Send to

Choose Destination
Expert Rev Clin Immunol. 2018 Oct;14(10):817-829. doi: 10.1080/1744666X.2018.1519396. Epub 2018 Sep 14.

Interferon activation in primary Sjögren's syndrome: recent insights and future perspective as novel treatment target.

Author information

a Department of Immunology , Erasmus University Medical Centre , Rotterdam , the Netherlands.


Primary Sjögren's syndrome (pSS) is one of the most common systemic autoimmune diseases. At the moment, there is no cure for this disease and its etiopathology is complex. Interferons (IFNs) play an important role in the pathogenesis of this disease and are a potential treatment target. Areas covered: Here we discuss the role of IFNs in pSS pathogenesis, complications encountered upon studying IFN-induced gene expression, and comment on the current knowledge on easy clinical applicable 'IFN signatures'. The current treatment options targeting IFNs in pSS are summarized and the perspective of potential new strategies discussed. Expert commentary: The authors provide their perspective on the role of IFNs in pSS and how this knowledge could be used to improve pSS diagnosis, provide new treatment targets, to monitor clinical trials and to stratify pSS patients in order to move toward precision medicine.


Primary Sjögren’s syndrome; biomarker; interferons; pathogenesis; stratification; treatment

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center